+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Comparison of adenosine versus iloprost by acute vasodilator test in patients of pulmonary arterial hypertension complicated with connective tissue diseases



Comparison of adenosine versus iloprost by acute vasodilator test in patients of pulmonary arterial hypertension complicated with connective tissue diseases



Zhonghua Yi Xue Za Zhi 89(30): 2099-2102



To compare the acute hemodynamic effects of adenosine versus iloprost in patients of pulmonary arterial hypertension (PAH) complicated with connective tissue diseases. During right heart catheterization, 18 patients of PAH complicated with connective tissue diseases sequentially received intravenous infusion of adenosine and inhaled iloprost. After the baseline hemodynamic data were obtained, an adenosine infusion was started and titrated to the maximal tolerated dose. The hemodynamic parameters were allowed to return to baseline. Then inhalation of iloprost was administered. The effects of both medicines on the patient's hemodynamics were monitored. As compared with the baseline values, the systolic pulmonary artery pressure and pulmonary vascular resistance significantly decreased [(71 +/- 30) vs (80 +/- 29) mm Hg and (712 +/- 440) vs (824 +/- 464) dyn x s x cm(-5) respectively, both P < 0.05) while the heart rate increased significantly [(93 +/- 17) vs (83 +/-16) beat/min, P < 0.05] in the adenosine group. Inhaled iloprost could also lower the systolic pulmonary artery pressure [(66 +/- 29) vs (79 +/- 28) mm Hg, P < 0.05], mean pulmonary artery pressure [(43 +/- 19) vs (52 +/- 19) mm Hg, P < 0.05] and pulmonary vascular resistance [(632 +/- 440) vs (816 +/- 448) dyn x s x cm(-5), P < 0.05] without any effect upon heart rate. Inhaled iloprost exerted more potent effect on lowering mean pulmonary artery pressure and pulmonary vascular resistance than adenosine (P < 0.05). The two medicines did not affect cardiac output, pulse oxygen saturation or systemic blood pressure. The side effects were fewer in the iloprost inhalation group than the adenosine group. During acute vasodilator testing, inhaled iloprost was more potent than infused adenosine as a pulmonary vasodilator in PAH complicated with connective tissue diseases.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 052228406

Download citation: RISBibTeXText

PMID: 20058611


Related references

Right-heart function related to the results of acute pulmonary vasodilator testing in patients with pulmonary arterial hypertension caused by connective tissue disease. Journal of the American Society of Echocardiography 25(3): 274-279, 2012

Long-term iloprost infusion therapy for severe pulmonary hypertension in patients with connective tissue diseases. Arthritis & Rheumatism. 37(10): 1528-1533, 1994

Acute hemodynamic responses to adenosine and iloprost in patients with congenital heart defects and severe pulmonary arterial hypertension. International Journal of Cardiology 147(3): 433-437, 2012

Pulmonary arterial hypertension in mixed connective tissue disease: successful treatment with Iloprost. Rheumatology International 26(3): 264-269, 2005

Pulmonary capillary endothelial metabolic dysfunction: severity in pulmonary arterial hypertension related to connective tissue disease versus idiopathic pulmonary arterial hypertension. Arthritis and Rheumatism 58(4): 1156-1164, 2008

Comparison of sitaxentan and bosentan in pulmonary arterial hypertension associated with connective tissue diseases. 2006

Pulmonary arterial hypertension among Filipino patients with connective tissue diseases. Modern Rheumatology 17(3): 224-227, 2007

Long-term outcomes of domiciliary intravenous iloprost in idiopathic and connective tissue disease-associated pulmonary arterial hypertension. Respirology 22(2): 372-377, 2016

SAT0320Coexistence of Left Heart Diseases is Common among Patients with Connective Tissue Diseases-Associated Pulmonary Arterial Hypertension. Annals of the Rheumatic Diseases 73(Suppl 2): 708.1-708, 2014

Frequency of pleural effusions in patients with pulmonary arterial hypertension associated with connective tissue diseases. Chest 140(1): 42-47, 2011

Undiagnosed connective tissue diseases: High prevalence in pulmonary arterial hypertension patients. Medicine 95(39): E4827, 2017

Treatment of Vasodilator-resistant Mixed Connective Tissue Disease-associated Pulmonary Arterial Hypertension with Glucocorticoid and Cyclophosphamide. Internal Medicine 56(4): 445-448, 2017

Early detection of pulmonary arterial hypertension by the exercise echocardiography in patients with connective tissue diseases. Life Sciences 93(25-26): e48, 2013

Prevalence of pulmonary arterial hypertension in patients with connective tissue diseases: a systematic review of the literature. Clinical Rheumatology 32(10): 1519-1531, 2014

Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension. European Respiratory Journal 33(6): 1354-1360, 2009